Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Registry facet

Compound monographs in the registry — page 2

51 documents of type compound monograph.

Documents

51 documents · page 2 of 2
  • CEI-MN-023Compound monograph2023-q2

    Growth-hormone-releasing hormone analogue with albumin-binding drug affinity complex. Both variants are GHRH receptor agonists that increase pulsatile growth-hormone secretion and, downstream, IGF-1. The DAC variant…

    Low14 Jul 2024
  • CEI-MN-002Compound monograph2023-q3

    GLP-1 receptor agonist, oral formulation with absorption enhancer. Receptor pharmacology is identical to subcutaneous semaglutide. The distinguishing pharmacology is absorption: SNAC buffers the gastric…

    High28 Jun 2024
  • CEI-MN-029Compound monograph2024-q1

    Recombinant insulin-like growth factor 1 analogue. IGF-1 receptor agonism with greatly reduced binding-protein sequestration. The consequence is a sustained, unbuffered IGF-1 receptor signal. Because…

    Very low18 Jun 2024
  • CEI-MN-030Compound monograph2023-q1

    Synthetic pentadecapeptide derived from a gastric juice protein sequence. The proposed mechanism is angiogenic and cytoprotective action through VEGF receptor 2 transactivation and nitric-oxide-pathway modulation…

    Very low11 May 2024
  • CEI-MN-026Compound monograph2023-q4

    Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide). Ghrelin receptor agonism producing growth-hormone release. Its approved use is a single-dose provocative diagnostic test, for which the acute…

    Low17 Apr 2024
  • CEI-MN-025Compound monograph2023-q1

    Growth-hormone secretagogue, non-selective ghrelin receptor agonist (hexapeptide). Hexarelin is a potent ghrelin receptor agonist producing marked growth-hormone release. Unlike ipamorelin it also stimulates…

    Very low10 Mar 2024
  • CEI-MN-034Compound monograph2023-q1

    C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone. KPV inhibits NF-κB activation and reduces pro-inflammatory cytokine production in epithelial and immune cells. Reported uptake through the…

    Very low01 Mar 2024
  • CEI-MN-020Compound monograph2023-q2

    GLP-2 receptor agonist. GLP-2 receptor agonism promotes intestinal mucosal growth, increases villus height and crypt depth, slows gastric emptying and reduces intestinal…

    Moderate30 Jan 2024
  • CEI-MN-051Compound monograph2023-q3

    Endogenous decapeptide, gonadotropin-releasing hormone. Gonadorelin stimulates pituitary release of luteinising hormone and follicle-stimulating hormone. Its pharmacology is dominated by a pattern…

    Moderate18 Jan 2024
  • CEI-MN-032Compound monograph2023-q2

    43-residue actin-sequestering polypeptide. Thymosin beta-4 sequesters monomeric actin and thereby regulates cytoskeletal dynamics, cell migration and wound repair. Extracellular administration…

    Low13 Dec 2023
  • CEI-MN-004Compound monograph2023-q1

    Triple GIP, GLP-1 and glucagon receptor agonist (acylated). Retatrutide adds glucagon receptor agonism to the dual incretin mechanism. Glucagon receptor activation increases hepatic fatty-acid oxidation and…

    Moderate19 May 2023

page 2 of 2

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.